Valproic Acid Oral Solution Recalled for Manufacturing Compliance Deviation
Akorn, Inc. is recalling all lots of Valproic Acid Oral Solution, USP (250mg/5mL) nationwide. The recall was issued because the firm ceased operations and could not complete required stability studies as mandated by manufacturing regulations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a prescription drug where required stability studies were not completed due to manufacturer closure. Although no illnesses or injuries have been reported, the inability to confirm ongoing safety and efficacy of the medication over its shelf life represents a risk-of-harm product where injury has not yet been reported, meeting the criterion for High severity.
Plain-English summary
Akorn, Inc. is recalling all lots of Valproic Acid Oral Solution, USP (250mg/5mL), distributed nationwide in the United States and Puerto Rico. The product is a prescription medication supplied in 473 mL bottles and distributed by Akorn Operating Company LLC, Gurnee, Illinois.
The recall was issued due to Current Good Manufacturing Practice (CGMP) deviations. The recalling firm ceased business operations and was unable to continue the stability studies required by federal manufacturing standards. Stability studies are essential to verify that a drug remains safe and effective throughout its shelf life.
This recall affects all patients who are currently using this product. All lots of the affected product are subject to recall.
Patients taking Valproic Acid Oral Solution should contact their pharmacy or healthcare provider regarding this recall and discuss next steps for their treatment.
The recalled product
- Product
- Valproic Acid Oral Solution, USP, 250mg/5mL, 473 mL bottles, Rx only, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19